against the LU-1, Hep-G2, MCF-7 and SW480 human cancer cell lines were significantly improved compared to those of azazerumbone or zerumbone. The anti-proliferative activities of (3E,7E,11E)-1-((1-(2-(3-hydroxy-4-((E)-3-(3-methoxyphenyl)acryloyl)phenoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-5,5,8,12-tetramethyl azacyclododeca-3,7,11-trien-2-one (9b) and (3E,7E,11E)-1-(3-(4-((E)-3-(3,4,5-trimethoxyphenyl)a
进行了氮杂
氮酮((3 E,7 E,11 E)-5,5,8,12-四甲基
氮杂环十二烷基-3,7,11-
三烯-2-酮(7))和2,4-二羟基
查耳酮的共轭反应用于制备新型目标化合物9a – g,带有
1-乙烯-4-亚甲基-
1,2,3-三唑连接基,10a – f,带有
丙烯连接基,位于氮杂zer酮的酰胺氮和
查耳酮的
4-羟基之间。与氮杂
氮酮或泽仑骨相比,这些化合物对LU-1,Hep-G2,MCF-7和SW480人癌
细胞系的抗增殖活性得到了显着改善。(3 E,7 E,11 E)-1-((1-(2-(3-羟基-4-((E)-3-(3-
甲氧基苯基)
丙烯酰基)苯氧基)乙基)-1 H -
1,2,3-三唑-4-基)甲基)-5,5,8,12-四甲基
氮杂环十二烷基-3,7,11-
三烯-2-酮(9b)和(3 E,7 E,11 E)-1-(3- (4-((E)-3-(3,4,5-三
甲氧基苯基)
丙烯酰基)苯氧基)丙基-5,5